A phase 1/2 first in human study of ADI-270, an armored allogeneic antiCD70 chimeric antigen receptor (CAR).dT cell therapy, in patients (pts) with relapsed or refractory (R/R) clear cell renal cell carcinoma (ccRCC) (trial in progress) Free

Category Primary study
JournalCANCER RESEARCH
Year 2025
This article has no abstract
Epistemonikos ID: d63fb0da97388493a17557fef6825bc430ba2a08
First added on: Jul 05, 2025